Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OHRP Moving .20 - interesting trades today
As soon as we have a little guidance and forward looking statements from the company, we should see a slight pop to the north.
Any statement would be great at this time.
We should all start calling OHRP and ask what the plan is going forward in spite of recent failures!
No news yet, however, slowly is gonna go back to 0.31¢
With no news stock is gonna go back down to 0.20¢ however is gonna bounce back very high, over 0.50¢
I really hope this stock falls very badly down to 0.25¢, I need to buy more at 0.25¢ (already have a bid for another $8,000)
this will skyrocket tomorrow ..
we will see 0.60 tomorrow
Do you know what happened to this stock? It went from trading on the NASDAQ to now trading on the OTC @ .33. I'm new here. I saw the litigation news. Is there hope for this stock to recover to it's original PPS?
Positioned at (Avg) 0.225¢ (Avg) invested $24,000 .... This is sweeeet
* * $OHRP Video Chart 06-12-18 * *
Link to Video - click here to watch the technical chart video
For reference purposes, RHE (Regional Health Properties) did something similar a couple of weeks ago.
I don't expect to be free in the morning, which is the main reason I dumped this before the close.
So, if you are holding, look to sell into some continuation move.
Something is up with this stock? Not many shares left???insiders must know something!!!
Looks like it might have been a technical bounce.
Then more people because of FOMO.
I bought $0.28s and sold $0.32s the same day.
Might see some continuation tomorrow, but if there is a lot of people stuck, they will start coming out.
Close to 15% for me in half a day.
Looking for the next one.
Hoping Roth Capital has them on the right path, and they are preparing to announce something. Fingers crossed.
https://www.sec.gov/Archives/edgar/data/1173281/000138713118002211/ohrp-10q_033118.htm
Recent Developments
On January 5, 2018, the Company reported topline data from the MAKO study which did not meet its primary efficacy endpoint. The MAKO study evaluated the efficacy and safety of topically administered squalamine in combination with monthly Lucentis® injections for the treatment of wet-AMD. The primary efficacy endpoint was the mean visual acuity gain at nine months, using a mixed effects model for repeated measures (MMRM) analysis. Subjects receiving squalamine combination therapy (n=119) achieved a mean gain of 8.33 letters from baseline versus 10.58 letters from baseline with Lucentis® monotherapy (n=118). There were no differences in the safety profile between the two treatment groups. Based on these results, we have discontinued further development of squalamine and are evaluating strategic alternatives to maximize shareholder value.
As part of its review of strategic alternatives, the Company formed a special committee of independent directors. The Board of Directors and the special committee have engaged Roth Capital Markets, LLC, to advise it, the Board of Directors and management, and to assist in pursuing a range of strategic alternatives including some of the following: license, divestiture, or other monetization of current assets; license or acquisition of additional assets; merger, joint venture, partnership, or other business combination with another entity, public or private. Neither the Board nor the special committee has set a definitive timetable for completion of this process. There can be no assurance that this process will result in a strategic alternative of any kind. The Company does not intend to disclose developments or provide updates on the progress or status of this process unless it deems further disclosure is appropriate or required.
insider buying ready for boomm!!!
some buying here. Could bounce hard with more volume!
OHRP has moved up 24% today, there's no news I can find. What say you?
OHRP has moved up 24% today, there's no news I can find. What say you?
I've gone over every article and docs concerning the continued failure of MAKO/Squalamine. I haven't found any data to suggest a way forward to turn pps around. What say you?
No. It’s worthless.
Shaka Sill holding?
looks like bottom is in there. Very cheap at this price level. Could bounce huge the next days/weeks. Long!
Great curriculum ¡¡ Will it save the company ?
https://www.linkedin.com/in/june-almenoff-md-phd-facp-73a5bab/?locale=es_ES
Innovate Biopharmaceuticals appoints June Almenoff, M.D., Ph.D. as Chief Operating Officer and Chief Medical Officer
Dr. Almenoff brings more than 20 years of pharmaceutical executive experience from GlaxoSmithKline and from Furiex Pharmaceuticals, where as President and Chief Medical Officer, she oversaw the development of Viberzi®. Almenoff will lead the development of Innovate’s pipeline including the upcoming Phase 3 program for celiac disease.
Innovate Biopharmaceuticals, Inc. (Nasdaq:INNT), a clinical stage biotechnology company focused on developing novel autoimmune and inflammation therapeutics, announced today Dr. June Almenoff has been appointed Chief Operating Officer and Chief Medical Officer. Dr. Almenoff brings a strong track record of success in biopharma leadership.
Dr. Almenoff was previously President and Chief Medical Officer at Furiex Pharmaceuticals, where during her 4-year tenure the company’s valuation increased ~10-fold, culminating in its acquisition by Actavis plc (now Allergan) for more than $1.2B in 2014. Furiex’s lead product, eluxadoline (Viberzi®), a novel gastrointestinal drug, is approved in both the US and EU. Prior to joining Furiex, Dr. Almenoff held various positions of increasing responsibility at GlaxoSmithKline PLC. During her 12 years at GSK, she was a Vice-President in the Clinical Safety organization, chaired a PhRMA-FDA working group and worked in scientific licensing. Dr. Almenoff also led the development of pioneering systems for minimizing risk in drug development, which has been widely adopted by industry and regulators.
Since 2015, Dr. Almenoff has been the Chair of RDD Pharma, a private, GI clinical stage biopharma company. She serves on the Boards of Directors of Tigenix NV (Nasdaq:TIG) since 2016, Brainstorm Therapeutics (Nasdaq:BCLI) since 2017, and Ohr Pharmaceutical (Nasdaq:OHRP) since 2013. Dr. Almenoff serves on the investment advisory board of the Harrington Discovery Institute. She has recently been a consultant and advisor to numerous biopharma companies in the areas of translational medicine, clinical development and commercial strategy in product development.
“Dr. Almenoff’s tremendous business leadership experience makes her an outstanding fit for Innovate,” said Sandeep Laumas, M.D., Executive Chair of Innovate. “June’s successes at Furiex and extensive experience in drug development, coupled with her scientific and business leadership, make us confident that she will provide meaningful contributions to the Company, beginning with our celiac disease program. As our pipeline continues to expand with indications such as NASH and inflammatory bowel disease, we are thrilled to have someone of June’s caliber lead their development and commercial strategy.”
“I am delighted to join Innovate at this transformative time for the company,” said Dr. June Almenoff. I believe that the Company has the potential to build an outstanding autoimmune franchise in GI therapeutics.”
Dr. Almenoff received her B.A. cum laude from Smith College, graduated with AOA honors from the M.D.-Ph.D. program at the Icahn (Mt. Sinai) School of Medicine and completed post-graduate medical training at Stanford University Medical Center (Internal Medicine, Infectious Diseases). Dr. Almenoff served on the faculty of Duke University School of Medicine, is an adjunct Professor at Duke and is a Fellow of the American College of Physicians.
About Innovate Biopharmaceuticals, Inc.:
Innovate is a clinical stage biotechnology company focused on developing novel autoimmune and inflammation therapeutic drugs. Innovate’s lead drug candidate, larazotide acetate (INN-202), has a mechanism of action which decreases intestinal permeability and regulates tight junctions by reducing antigen trafficking across intestinal epithelial cells. In several autoimmune diseases, including celiac disease, nonalcoholic steatohepatitis (NASH), inflammatory bowel diseases (IBD, Crohn’s disease and ulcerative colitis), irritable bowel syndrome (IBS), type 1 diabetes mellitus (T1DM), chronic kidney disease (CKD) and others, intestinal permeability is increased, also referred to as “leaky gut,” and to our knowledge, larazotide is the only drug in clinical testing which reduces permeability.
In celiac disease, larazotide is the only drug which has successfully met the primary endpoint with statistical significance in a 342-patient Phase 2b efficacy clinical trial. Innovate successfully completed the End of Phase 2 Meeting with the FDA in 2017 and is preparing for larazotide to begin Phase 3 clinical trials for celiac disease targeted for the second half of 2018. In clinical trials testing more than 800 patients, larazotide demonstrated a favorable safety profile comparable to placebo, especially due to its lack of systemic absorption from the small intestines. Larazotide has also received Fast Track designation from the FDA for celiac disease.
For more information, please visit www.innovatebiopharma.com.
Forward Looking Statements for Innovate Biopharmaceuticals, Inc.
This press release includes forward-looking statements including, but not limited to, statements related to the potential for Innovate’s drug development pipeline candidates in treating the diseases and conditions for which they are being developed, Innovate’s start of clinical trials for celiac disease, NASH, Crohn’s disease, and ulcerative colitis, and Innovate’s ability to develop future collaborations. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, the success, timing and cost of ongoing or future clinical trials, the lengthy and unpredictable nature of the drug approval process, and our ability to commercialize our product candidates if approved. These risks and uncertainties include, but may not be limited to, those described in our Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 2, 2018, and in any subsequent filings with the SEC. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.
Innovate Biopharmaceuticals, Inc.
Kendyle Woodard
Tel: 919-275-1933
Email: investor.relations@innovatebiopharma.com
www.innovatebiopharma.com
What happened to go down from $ 2.2 to $ 0.4 ?
Can someone update me about this company ?
For the quarter ended December 31, 2017, the Company reported a net loss of approximately $4.2 million, or ($0.07) per share, compared to a net loss of approximately $7.0 million, or ($0.21) per share in the same period of 2016.
For the quarter ended December 31, 2017, total operating expenses were approximately $4.2 million, consisting of $1.5 million in general and administrative expenses, $2.4 million of research and development expenses, and $0.3 million in depreciation and amortization. This compares to total operating expenses of $7.0 million in the same period of 2016, comprised of approximately $1.7 million in general and administrative expenses, $4.9 million in research and development expenses, and $0.3 million in depreciation and amortization.
At December 31, 2017, the Company had cash and cash equivalents of approximately $8.7 million. This compares to cash and equivalents of approximately $12.8 million at September 30, 2017.
Nupapa thanks for the insight! I don't have great confidence they can improve on Squalamine yet it seems like the best short-term play vs starting from scratch. Yeh, I doubled down also
IMO - The only option for OHRP is to start trials on a new drug, or find another use for squalamine. If they don't, it's game over. And they need to do something soon to give shareholders some sort of optimism. I bought in near $1.60 and I've doubled my position for now. Not putting another dime in until they make some announcements.
Nupapa
Interesting's let see rekindles driving the stocks backed ups. Steady buys today. patience for the recovery. I'm believing it wills.
Worth .15 cents a share 8.7m cash on hand. That’s it. Good luck.
Real value to strike the balance between management an its reunites retunes our stock an progressions $OHRP.
Your sure. DD these corrections might be at the forwards hands.
Me too, all good.
This looks like it's going now..
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=127746470
Nope. Took a small loss. On to the next
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a pharmaceutical company developing therapies for ophthalmic diseases, today reported financial results and operating highlights for its fiscal first quarter ended December 31, 2017.
“We recently announced top-line results from the MAKO study evaluating the efficacy and safety of topically administered squalamine in combination with monthly Lucentis® injections for the treatment of wet-AMD, which did not meet its primary efficacy endpoint,” said Dr. Jason Slakter, chief executive officer of Ohr Pharmaceutical. “Based on these results, we have discontinued development of squalamine, taken measures to preserve cash and are evaluating strategic alternatives to maximize shareholder value.”
Corporate Highlights for the Fiscal First Quarter Ended December 31, 2017
Reported topline data from the MAKO study which did not meet its primary efficacy endpoint. There were no differences in the safety profile between the two treatment groups. The MAKO study evaluated the efficacy and safety of topically administered squalamine in combination with monthly Lucentis® injections for the treatment of wet age-related macular degeneration (“wet-AMD”). Based on the results, the Company has discontinued further development of squalamine and is evaluating strategic alternatives.
The Board of Directors has engaged Roth Capital Markets, LLC, to advise the Board of Directors and management, and to assist in pursuing a range of strategic alternatives.?
Financial Results for the Quarter ended December 31, 2017
For the quarter ended December 31, 2017, the Company reported a net loss of approximately $4.2 million, or ($0.07) per share, compared to a net loss of approximately $7.0 million, or ($0.21) per share in the same period of 2016.
For the quarter ended December 31, 2017, total operating expenses were approximately $4.2 million, consisting of $1.5 million in general and administrative expenses, $2.4 million of research and development expenses, and $0.3 million in depreciation and amortization. This compares to total operating expenses of $7.0 million in the same period of 2016, comprised of approximately $1.7 million in general and administrative expenses, $4.9 million in research and development expenses, and $0.3 million in depreciation and amortization.
At December 31, 2017, the Company had cash and cash equivalents of approximately $8.7 million. This compares to cash and equivalents of approximately $12.8 million at September 30, 2017.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and we undertake no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to raise sufficient funds to perform and conclude clinical trials, the financial resources available to us, the ability to negotiate and conclude a strategic partnership, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, and general economic conditions. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA will approve final testing or marketing of any pharmaceutical product. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition.
Contact:
Ohr Pharmaceutical Inc.
Investor Relations
888-388-2327
ir@ohrpharmaceutical.com
Break out after these 17k shares at .3172
Followers
|
27
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
612
|
Created
|
11/27/06
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |